Table 1.
Clinicopathologic summary of the study cohort
| Diagnosis | Female, n (%) | Male, n (%) | Mean age in years (range) | Median tumor size in cm (range) | Top primary site | Metastasis, n (%) | Top metastatic site | Total |
|---|---|---|---|---|---|---|---|---|
| Angiomatoid fibrous histiocytoma | 19 (53) | 17 (47) | 28.3 (2–79) | 3.4 (1.0–10.5) | Lower extremities, upper extremities, head and neck, trunk | 4 (11) | Lung, bone, adrenal | 36 |
| Clear cell odontogenic carcinoma | 1 (100) | 0 | 57.0 | 2.7 | Head and neck | 0 | N/A | 1 |
| Clear cell sarcoma | 16 (40) | 24 (60) | 32.9 (7–71) | 4.7 (2.5–12.0) | Lower extremities, upper extremities | 18 (45) | Lymph node, lung | 40 |
| Clear cell sarcoma-like tumor of the gastrointestinal tract | 14 (70) | 6 (30) | 39.0 (18–76) | 4.5 (2.5–6.0) | Gastrointestinal tract | 8 (40) | Liver, abdominopelvic | 20 |
| Hyalinizing clear cell carcinoma of salivary gland | 8 (80) | 2 (20) | 67.6 (55–86) | 2.1 (1.3–3.3) | Salivary gland | 3 (30) | Lymph node, trunk, abdominopelvic | 10 |
| Malignant epithelioid neoplasm with predilection for mesothelial-lined cavities | 7 (50) | 7 (50) | 37.2 (9–63) | 9.0 (4.5–15.0) | Abdominopelvic | 3 (21) | Lymph node, liver abdominopelvic | 14 |
| Mesothelioma | 5 (62) | 3 (38) | 39.0 (15–78) | 3.8 (2.6–8.5) | Abdominopelvic, pleura | 2 (25) | Lymph node, abdominopelvic | 8 |
| Myxoid mesenchymal tumor | 3 (60) | 2 (40) | 27.0 (12–48) | 2.9 (2.8–3.0) | Brain | 0 | N/A | 5 |
| Primary pulmonary myxoid sarcoma | 3 (100) | 0 | 59.0 (43–82) | 1.4 | Lung | 1 (33) | Lymph node | 3 |
| Total | 76 | 61 | 36.4 (5–86) | 4.0 | 39 (28) | 137 |